These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

859 related items for PubMed ID: 26281189

  • 1. [Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].
    Milovanova LY, Milovanov YS, Kudryavtseva DV, Markina MM, Milovanova SY, Kozlovskaya LV, Lebedeva MV, Beketov VD, Moiseev SV, Mukhin NA, Fomin VV, Svistunov AA.
    Ter Arkh; 2015; 87(6):10-16. PubMed ID: 26281189
    [Abstract] [Full Text] [Related]

  • 2. [New markers of cardio-renal links in chronic kidney disease].
    Milovanova LIu, Milovanov IuS, Kozlovskaia LV, Mukhin NA.
    Ter Arkh; 2013; 85(6):17-24. PubMed ID: 23866594
    [Abstract] [Full Text] [Related]

  • 3. [MORPHOGENETIC PROTEINS--FIBROBLAST GROWTH FACTOR AND KLOTHO, IN THE SERA OF PATIENTS WITH CHRONIC RENAL DISEASE].
    Milovanova LY, Kozlovskaya LV, Markina MM, Milovanova SY, Borisov AA, Mukhin NA, Fomin VV, Moiseev SV.
    Klin Med (Mosk); 2015; 93(12):32-8. PubMed ID: 27149811
    [Abstract] [Full Text] [Related]

  • 4. [Significance of the morphogenetic proteins FGF-23 and Klotho as predictors of prognosis of chronic kidney disease].
    Milovanova LIu, Milovanov IuS, Kozlovskaia LV, Mukhin NA.
    Ter Arkh; 2014; 86(4):36-44. PubMed ID: 24864466
    [Abstract] [Full Text] [Related]

  • 5. [Decreased Serum Levels of Klotho Protein in Chronic Kidney Disease Patients: Clinical Imortance].
    Milovanova LY, Mukhin NA, Kozlovskaya LV, Milovanov YS, Kiyakbaev GG, Rogova IV, Lebedeva MV, Androsova TV, Milovanova SY, Gil AY, Taranova MV.
    Vestn Ross Akad Med Nauk; 2016; 71(4):288-96. PubMed ID: 29297646
    [Abstract] [Full Text] [Related]

  • 6. Fibroblast growth factor-23 (FGF-23) / soluble Klotho protein (sKlotho) / sclerostin glycoprotein ratio disturbance is a novel risk factor for cardiovascular complications in ESRD patients receiving treatment with regular hemodialysis or hemodiafiltration.
    Milovanova LY, Dobrosmyslov IA, Milovanov YS, Taranova MV, Kozlov VV, Milovanova SY, Kozevnikova EI.
    Ter Arkh; 2018 Jun 20; 90(6):48-54. PubMed ID: 30701904
    [Abstract] [Full Text] [Related]

  • 7. Serum bone markers in ROD patients across the spectrum of decreases in GFR: Activin A increases before all other markers
.
    Lima F, Mawad H, El-Husseini AA, Davenport DL, Malluche HH.
    Clin Nephrol; 2019 Apr 20; 91(4):222-230. PubMed ID: 30862350
    [Abstract] [Full Text] [Related]

  • 8. The association between soluble klotho and cardiovascular parameters in chronic kidney disease: results from the KNOW-CKD study.
    Kim HJ, Kang E, Oh YK, Kim YH, Han SH, Yoo TH, Chae DW, Lee J, Ahn C, Oh KH.
    BMC Nephrol; 2018 Mar 05; 19(1):51. PubMed ID: 29506503
    [Abstract] [Full Text] [Related]

  • 9. The FGF23-Klotho axis and cardiac tissue Doppler imaging in pediatric chronic kidney disease-a prospective cohort study.
    Tranæus Lindblad Y, Olauson H, Vavilis G, Hammar U, Herthelius M, Axelsson J, Bárány P.
    Pediatr Nephrol; 2018 Jan 05; 33(1):147-157. PubMed ID: 28795324
    [Abstract] [Full Text] [Related]

  • 10. [Fibroblast growth factor 23 and a novel high-sensitivity troponin I: Early markers and alternative ways of damaging the heart in chronic kidney disease].
    Dzgoeva FU, Sopoev MY, Gatagonova TM, Bestaeva TL, Khamitsaeva OV.
    Ter Arkh; 2015 Jan 05; 87(6):68-74. PubMed ID: 26281199
    [Abstract] [Full Text] [Related]

  • 11. [EVALUATION OF CARDIOVASCULAR RISKS WITH THE USE OF MORPHOGENETIC KLOTHO PROTEIN IN PATIENTS WITH CHRONIC RENAL DISEASE].
    Mukhin NA, Milovanova LY, Fomin VV, Kozlovskaya LV, Taranova MV, Androsova TV, Borisov AA.
    Klin Med (Mosk); 2017 Jan 05; 95(3):272-7. PubMed ID: 30303650
    [Abstract] [Full Text] [Related]

  • 12. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection].
    Milovanov YS, Mukhin NA, Kozlovskaya LV, Milovanova SY, Markina MM.
    Ter Arkh; 2016 Jan 05; 88(6):21-25. PubMed ID: 27296257
    [Abstract] [Full Text] [Related]

  • 13. Serum sclerostin and adverse outcomes in nondialyzed chronic kidney disease patients.
    Kanbay M, Siriopol D, Saglam M, Kurt YG, Gok M, Cetinkaya H, Karaman M, Unal HU, Oguz Y, Sari S, Eyileten T, Goldsmith D, Vural A, Veisa G, Covic A, Yilmaz MI.
    J Clin Endocrinol Metab; 2014 Oct 05; 99(10):E1854-61. PubMed ID: 25057883
    [Abstract] [Full Text] [Related]

  • 14. Uremic toxicity and sclerostin in chronic kidney disease patients.
    Desjardins L, Liabeuf S, Oliveira RB, Louvet L, Kamel S, Lemke HD, Vanholder R, Choukroun G, Massy ZA, European Uremic Toxin (EUTox) Work Group.
    Nephrol Ther; 2014 Nov 05; 10(6):463-70. PubMed ID: 25070604
    [Abstract] [Full Text] [Related]

  • 15. Circulating α-klotho levels in CKD and relationship to progression.
    Kim HR, Nam BY, Kim DW, Kang MW, Han JH, Lee MJ, Shin DH, Doh FM, Koo HM, Ko KI, Kim CH, Oh HJ, Yoo TH, Kang SW, Han DS, Han SH.
    Am J Kidney Dis; 2013 Jun 05; 61(6):899-909. PubMed ID: 23540260
    [Abstract] [Full Text] [Related]

  • 16. Plasmatic Klotho and FGF23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients.
    Silva AP, Mendes F, Carias E, Gonçalves RB, Fragoso A, Dias C, Tavares N, Café HM, Santos N, Rato F, Leão Neves P, Almeida E.
    Int J Mol Sci; 2019 Mar 27; 20(7):. PubMed ID: 30934737
    [Abstract] [Full Text] [Related]

  • 17. Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease.
    Seifert ME, de las Fuentes L, Ginsberg C, Rothstein M, Dietzen DJ, Cheng SC, Ross W, Windus D, Dávila-Román VG, Hruska KA.
    Am J Nephrol; 2014 Mar 27; 39(5):392-9. PubMed ID: 24818573
    [Abstract] [Full Text] [Related]

  • 18. Fibroblast Growth Factor 23 and α-Klotho Protein Are Associated with Adverse Clinical Outcomes in Non-Dialysis CKD Patients.
    Manou E, Thodis E, Arsos G, Pasadakis P, Panagoutsos S, Papadopoulou D, Papagianni A.
    Kidney Blood Press Res; 2020 Mar 27; 45(6):900-915. PubMed ID: 33040068
    [Abstract] [Full Text] [Related]

  • 19. [Correlations of FGF23 and Klotho with cardiovascular injury in chronic kidney disease patients].
    Gan L, Zhou Q.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Sep 28; 42(9):1058-1065. PubMed ID: 28989152
    [Abstract] [Full Text] [Related]

  • 20. [Effects of keto/amino acids and a low-protein diet on the nutritional status of patients with Stages 3B-4 chronic kidney disease].
    Milovanova SY, Milovanov YS, Taranova MV, Dobrosmyslov IA.
    Ter Arkh; 2017 Sep 28; 89(6):30-33. PubMed ID: 28745686
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 43.